What Evidence Can and Cannot Show About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Risk Assessment

If you're taking Ozempic and experiencing persistent nausea, bloating, or abdominal pain, you may be concerned about gastroparesis—a condition where the stomach empties too slowly. Decades of pharmacovigilance have established that delayed gastric emptying can occur with GLP-1 receptor agonists, but determining causation in individual cases requires careful analysis. This page reviews what monitoring and follow-up tests can—and cannot—tell us about the link between Ozempic and gastroparesis.

Clinical Evidence Linking Ozempic to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have raised concerns about a potential link to gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, Ozempic's pharmacology and reported adverse effects, mechanistic pathways, and risk considerations for affected patients, including legal aspects. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy showing delayed emptying. The condition can lead to malnutrition, dehydration, and impaired quality of life. Ozempic's mechanism of action includes slowing gastric emptying as part of its glucose-lowering effect, which is mediated by GLP-1 receptor activation. This pharmacological effect can exacerbate or unmask gastroparesis in susceptible individuals. Clinical trial data from the Ozempic prescribing information document a higher incidence of gastrointestinal adverse reactions compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic groups (0.5 mg: 3.1%; 1 mg: 3.8%) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with frequencies below 5% included dyspepsia (placebo: 1.9%; 0.5 mg: 3.5%; 1 mg: 2.7%), eructation (0%; 2.7%; 1.1%), flatulence (0.8%; 0.4%; 1.5%), gastroesophageal reflux disease (0%; 1.9%; 1.5%), and gastritis (0.8%; 0.8%; 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not specifically list gastroparesis, the spectrum of symptoms overlaps with gastroparesis presentation.

Mechanistic Pathways and Risk Factors

Mechanistically, GLP-1 receptor agonists like Ozempic inhibit gastric motility and slow gastric emptying. This effect is dose-dependent and can persist with chronic use. In patients with pre-existing delayed gastric emptying or those taking other medications that slow gastrointestinal transit, Ozempic may increase the risk of developing gastroparesis. The label does not explicitly warn about gastroparesis, but it does caution about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning raises questions about the adequacy of risk communication. For patients who develop gastroparesis after starting Ozempic, the timeline between exposure and harm is critical. Symptoms often emerge during dose escalation, as noted in clinical trials where gastrointestinal adverse reactions were most common during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, delayed onset is possible, and the condition may persist after drug discontinuation. Medical evaluation should include gastric emptying studies and exclusion of other causes.

Legal Considerations and Settlement Criteria

Attorney-related considerations for affected patients involve assessing whether the manufacturer provided adequate warnings. The current label lists gastrointestinal adverse reactions but does not specifically mention gastroparesis. Patients who experienced severe or persistent symptoms may have grounds for a lawsuit if they can demonstrate that the drug caused their condition and that warnings were insufficient. Settlement criteria in such cases typically consider the severity of harm, duration of symptoms, medical expenses, lost wages, and evidence of inadequate warnings. The absence of a specific gastroparesis warning in the label could be a key factor in litigation. In summary, Ozempic is associated with a high rate of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The drug's mechanism of slowing gastric emptying provides a plausible link. Patients who develop gastroparesis after Ozempic use should seek medical evaluation and consider legal consultation to explore their options regarding inadequate warnings and potential compensation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can exacerbate or unmask gastroparesis in susceptible individuals. Clinical trials show high rates of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, though the label does not specifically warn about this condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for an Ozempic gastroparesis lawsuit?

Settlement criteria typically include severity of harm, duration of symptoms, medical expenses, lost wages, and evidence that the manufacturer failed to provide adequate warnings about the risk of gastroparesis. The absence of a specific gastroparesis warning in the label may strengthen a claim.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.